莫沙必利结合铝碳酸镁片治疗胆汁反流性胃炎的疗效分析

Analysis of the Efficacy and Adverse reactions of Mosapride Combined with Hydrotalcite Tablets in the Treatment of Bile Reflux Gastritis

目的探讨胆汁反流性胃炎(Bile reflux gastritis,BRG)在莫沙必利给药基础上,结合铝碳酸镁片治疗疗效及安全性。方法选取于2018年2月至2019年2月期间收治于南京市中心医院消化内科BRG患者90例,应用随机数字表法分组,对单用莫沙必利方案治疗(对照组,n=45)与结合铝碳酸镁片治疗(试验组,n=45)效果展开对比。结果 试验组临床总有效率经评定为97.78%,高于对照组82.22%(P<0.05);治疗前,两组胃液中胃酸分泌量及胆酸含量,差异无统计学意义(P>0.05),治疗后两组较治疗前均有减少,且试验组减少更明显(P<0.05);治疗前,两组胃镜下指标胃窦黏膜糜烂、水肿、充血评分,差异无统计学意义(P>0.05);治疗后较治疗前均有降低,且试验组各评分降低更明显(P<0.05);治疗前,两组炎性指标CRP、IL-8水平,差异无统计学意义(P>0.05),治疗后较治疗前均有降低,且试验组水平降低更明显(P<0.05);试验组不良反应率为2.22%,对照组为8.89%,差异无统计学意义(P>0.05)。结论BRG在莫沙必利给药基础上,结合铝碳酸镁片治疗,可提高临床疗效,改善胃内胃酸环境,保护胃黏膜,降低炎性反应,且具较高安全性,指导应用价值十分突出。

Objective To investigate the efficacy and safety of mosapride combined with hydrotalcite tablets in the treatment of bile reflux gastritis. Methods A total of 90 patients with bile reflux gastritis enrolled in Nanjing Central Hospital from February of 2018 to February of 2019 were selected and divided into the control group and observation group according to the random number table, and each group included 45 cases. The control group was treated with mosapride, while the observation group was treated with mosapride and hydrotalcite tablets. The efficacy was compared between the two groups. Results The total effective rate of the observation group (97.78%) was significantly higher than that of the control group (82.22%)( P <0.05). The gastric acid secretion and bile acid content before treatment were not significantly different between the two groups ( P >0.05), while those after treatment were reduced in both groups and the reduction degree was significantly greater in the observation group ( P <0.05). The scores of gastric antrum mucosal erosion, edema and hyperemia before treatment were not significantly different between the two groups ( P >0.05), while those after treatment were decreased in both groups and the decreases were more significant in the observation group ( P <0.05). The levels of the inflammatory indicators including CRP and IL-8 before treatment were not significantly different between the two groups ( P >0.05), while those after treatment were decreased and the decreases were more significant in the observation group ( P <0.05). The rate of adverse reactions was 2.22% in the observation group and 8.89% in the control group, and the difference was not statistically significant ( P >0.05). Conclusion Mosapride combined with hydrotalcite tablets can improve the clinical efficacy by ameliorating the gastric acid environment, protecting the gastric mucosa and reducing the inflammatory reaction with higher safety in the treatment of bile reflux gastritis, so it is of prominent application value.